Outrun Therapeutics expands leadership team with appointment of Matthew Fyfe as Chief Scientific Officer
Published on 08/07/2025 at 18:08 | prnewswire.co.uk
Brings extensive small molecule drug discovery, development, and clinical experience across multiple therapeutic areasWill drive application of Outrun's novel, proprietary X-E3L platform for protein stabiliser discovery to develop a pipeline of high-quality drug candidates targeting E3 ligasesContinues strong momentum following 2024 emergence from stealth with $10M seed financingView original content:https://www.prnewswire.co.uk/news-releases/outrun-therapeutics-expands-leadership-team-with-appointment-of-matthew-fyfe-as-chief-scientific-officer-302348196.html
en | boerse | 67934783 |
